Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
The Scientific World Journal
Volume 2014, Article ID 284072, 6 pages
http://dx.doi.org/10.1155/2014/284072
Research Article

Environmentally Related Diseases and the Possibility of Valuation of Their Social Costs

Department of Environmental Health, Faculty of Public Health, Medical University of Silesia in Katowice, Ulica Piekarska 18, 41-902 Bytom, Poland

Received 10 July 2014; Accepted 1 September 2014; Published 14 October 2014

Academic Editor: Tullio Florio

Copyright © 2014 Ilona Hajok et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Chemicals and Our Health: Why Recent Science is a Call to Action,” Safer Chemicals Healthy Families. A national effort to protect families from toxic chemicals, 2012, http://saferchemicals.org/wp-content/uploads/sites/3/2013/09/chemicals-and-our-health-july-2013.pdf.
  2. R. Baan, Y. Grosse, K. Straif et al., “A review of human carcinogens. Part F. Chemical agents and related occupations,” The lancet oncology, vol. 10, no. 12, pp. 1143–1144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. P. J. Landrigan, C. B. Schechter, J. M. Lipton, M. C. Fahs, and J. Schwartz, “Environmental pollutants and disease in American children: estimates of morbidity, mortality, and costs for lead poisoning, asthma, cancer, and developmental disabilities,” Environmental Health Perspectives, vol. 110, no. 7, pp. 721–728, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Boyle, S. Boulet, L. A. Schieve et al., “Trends in the prevalence of developmental disabilities in US children, 1997–2008,” Pediatrics, vol. 127, no. 6, pp. 1034–1042, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Trasande and Y. Liu, “Reducing the staggering costs of environmental disease in children, estimated at $76.6 billion in 2008,” Health Affairs, vol. 30, no. 5, pp. 863–870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. L. Schantz, D. M. Gasior, E. Polverejan et al., “Impairments of memory and learning in older adults exposed to polychlorinated biphenyls via consumption of Great Lakes Fish,” Environmental Health Perspectives, vol. 109, no. 6, pp. 605–611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. W. M. Caudle, J. R. Richardson, K. C. Delea et al., “Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity,” Toxicological Sciences, vol. 92, no. 2, pp. 490–499, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Steenland, M. J. Hein, R. T. Cassinelli II et al., “Polychlorinated biphenyls and neurodegenerative disease mortality in an occupational cohort,” Epidemiology, vol. 17, no. 1, pp. 8–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. K. C. Lin, N. W. Guo, P. C. Tsai, C. Y. Yang, and Y. L. Guo, “Neurocognitive changes among elderly exposed to PCBs/PCDFs in Taiwan,” Environmental Health Perspectives, vol. 116, no. 2, pp. 184–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, vol. 68, no. 5, pp. 384–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Environmental Threats to Healthy Aging: with a closer look at Alzheimer’s and Parkinson’s diseases, “Greater Boston Physicians for Social Responsibility and Science and Environmental Health Network,” 2008, http://www.agehealthy.org/pdf/GBPSRSEHN_HealthyAging1017.pdf.
  12. J.-F. Heilier, J. Donnez, and D. Lison, “Organochlorines and endometriosis: a mini-review,” Chemosphere, vol. 71, no. 2, pp. 203–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Szeszenia-Dąbrowska, Asbestos: Occupational and Environmental Exposure: Effects, Prevention, Nofer Institute of Occupational Medicine, Łódź, Poland, 2004, (Polish).
  14. K. Marek, “Asbestos as the environmental harmfulness,” Medycyna Środowiskowa—Environmental Medicine, vol. 7, pp. 1–8, 2004, (Polish). View at Google Scholar
  15. M. Ezzati, A. D. Lopez, A. Rodgers et al., Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attribution to Selected Major Risk Factors, vol. 2, World Health Organization, Geneva, Switzerland, 2004.
  16. L. Kazan-Allen, “Asbestos and mesothelioma: worldwide trends,” Lung Cancer, vol. 49, no. 1, pp. S3–S8, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. B. T. Mossman and J. B. Gee, “Asbestos-related diseases,” The New England Journal of Medicine, vol. 320, no. 26, pp. 1721–1730, 1989. View at Publisher · View at Google Scholar · View at Scopus
  18. J. LaDou, “The asbestos cancer epidemic,” Environmental Health Perspectives, vol. 112, no. 3, pp. 285–290, 2004. View at Google Scholar · View at Scopus
  19. E. Więcek, “Asbestos-exposition and health effects,” Bezpieczeństwo Pracy, Nauka i Praktyka, vol. 2, pp. 2–6, 2004 (Polish). View at Google Scholar
  20. Elimination of Asbestos and Asbestos Contained Products Used in Poland 2002–2032, Warsaw, Poland, 2002, (Polish).
  21. B. P. Lanphear and C. R. Buncher, “Latent period for malignant mesothelioma of occupational origin,” Journal of Occupational Medicine, vol. 34, no. 7, pp. 718–721, 1992. View at Google Scholar · View at Scopus
  22. J. Niklinski, W. Niklinska, E. Chyczewska et al., “The epidemiology of asbestos-related diseases,” Lung Cancer, vol. 45, supplement 1, pp. S7–S15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. Ministry of Economy, The National Programme for Elimination of Asbestos. Plants that used asbestos in production, 2010, (Polish), http://www.mg.gov.pl/Bezpieczenstwo+gospodarcze/Program+Oczyszczania+Kraju+z+Azbestu/Informacja+o+Programie/Zaklady+ktore+stosowaly+azbest+w+produkcji.
  24. T. Bachelda-Curuś, Information on the Results of Audit of the Program for Disposal of Asbestos and Asbestos-Containing Products in 2003–2005, Supreme Audit Office, Warsaw, Poland, 2007.
  25. I. Hajok, Forecast of the health effects in population of Poles as a result of exposure to asbestos dust [Ph. D. thesis in Health Sciences], Medical University of Silesia, Katowice, Poland, 2011, (Polish).
  26. S. N. Wood, “Thin plate regression splines,” Journal of the Royal Statistical Society: Series B: Statistical Methodology, vol. 65, no. 1, pp. 95–114, 2003. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  27. World Health Organization (WHO), Air Quality Guidelines for Europe, WHO Regional Publications, European Series, No. 91, WHO Regional Office for Europe, Copenhagen, Denmark, 2nd edition, 2000.
  28. J. Peto, A. Decarli, C. la Vecchia, F. Levi, and E. Negri, “The European mesothelioma epidemic,” British Journal of Cancer, vol. 79, no. 3-4, pp. 666–672, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Łanda and M. Władysiuk-Blicharz, Podstawowe Cechy i Zasady Tworzenia Koszyków Świadczeń Zdrowotnych w Wybranych Krajach. (The Basic Features and Principles of Benefit Packages in Some Countries), HTA Consulting, Kraków, Poland, 2006, (Polish).
  30. The National Health Fund, Lung Cancer from the Perspective of the NHF, Reporting, and Cost of Treatment in the Years 2002–2010, National Health Fund, Warsaw, Poland, 2011, (Polish).
  31. J. Ruszkowski and J. Leśniowska, “Real, economic costs of the disease in Poland,” in Polish Association for Knowledge Management: Studies and Materials, vol. 25, 2010. View at Google Scholar
  32. M. Czech, Pharmacoeconomic in Pharmaceutical Care, Farmapress, Warsaw, Poland, 2008, (Polish).
  33. M. Czech, Pharmacoeconomics: Economic Assessment of Health Care Programs, Warsaw University of Technology, Warsaw, Poland, 2004, (Polish).
  34. P. Łupiński, “Pharmacoeconomics of cancer disease,” Współczesna Onkologia, vol. 5, pp. 67–71, 1998 (Polish). View at Google Scholar